ABSTRACT
Basal cell carcinoma (BCC) is the most common cutaneous malignancy, usually occurring in sun-exposed areas. Although BCC in the scrotal region is uncommon, it carries a higher risk of metastasis than BCC at other sites. Here, we report two cases of BCC that developed in the scrotal region: Case 1 presented as a superficial nodule and Case 2 as a subcutaneous nodule. Histopathologically, both tumors lacked continuity with the surface epidermis and formed an intradermal nodule. In Case 1, BCC occurred for the first time and presumably developed de novo. Case 2 underwent excision of a scrotal BCC 5 years previously, and the histopathological diagnosis at that time was nodular BCC. However, when the original specimen was re-examined, it was determined that, although the tumor had been completely resected, part of the lesion had moved away from the nodular area to represent a micronodular phenotype, an aggressive BCC subtype. We hypothesized that partial evolution from a nodular to a micronodular phenotype may have contributed to the recurrence of BCC in Case 2.
ABSTRACT
Purpose: The status of dupilumab self-injection at home is not well understood. We therefore aimed to identify the barriers to adherence to dupilumab self-injection. Patients and Methods: This non-interventional open-label study was conducted between March 2021 and July 2021. Patients with atopic dermatitis, bronchial asthma, and chronic rhinosinusitis with nasal polyps receiving dupilumab, from 15 sites, were requested to complete a self-administered questionnaire regarding the frequency and effectiveness of dosing as well as their use and satisfaction with dupilumab. Barriers to adherence were assessed using the Adherence Starts with Knowledge-12. Results: We included 331 patients who used dupilumab for atopic dermatitis (n = 164), chronic rhinosinusitis with nasal polyps (n = 102), and bronchial asthma (n = 65). The median efficacy of dupilumab scored 9.3 on the visual analog scale. Overall, 85.5% of the patients self-injected dupilumab, and 70.7% perfectly complied with the established injection dates. The pre-filled pen was significantly superior to the conventional syringe in terms of usability, operability, ease of pushing the plunger, and patient satisfaction. However, the pre-filled pen caused more pain during self-injection than did the syringe. Multivariate logistic regression analysis showed that adherence decreased with longer dupilumab treatment duration (p = 0.017) and was not associated with age, sex, underlying disease, or device type. There was a difference in responses related to "inconvenience/forgetfulness" between the good and poor adherence groups. Conclusion: The pre-filled dupilumab pen was superior to the syringe in terms of usability, operability, ease of pushing the plunger, and satisfaction. Repetitive instructions are recommended for preventing poor adherence to dupilumab self-injection.
ABSTRACT
Vertebrates exhibit patterned epidermis, exemplified by scales/interscales in mice tails and grooves/ridges on the human skin surface (microtopography). Although the role of spatiotemporal regulation of stem cells (SCs) has been implicated in this process, the mechanism underlying the development of such epidermal patterns is poorly understood. Here, we show that collagen XVII (COL17), a niche for epidermal SCs, helps stabilize epidermal patterns. Gene knockout and rescue experiments revealed that COL17 maintains the width of the murine tail scale epidermis independently of epidermal cell polarity. Skin regeneration after wounding was associated with slender scale epidermis, which was alleviated by overexpression of human COL17. COL17-negative skin in human junctional epidermolysis bullosa showed a distinct epidermal pattern from COL17-positive skin that resulted from revertant mosaicism. These results demonstrate that COL17 contributes to defining mouse tail scale shapes and human skin microtopography. Our study sheds light on the role of the SC niche in tissue pattern formation.
Subject(s)
Autoantigens , Epidermis , Non-Fibrillar Collagens , Animals , Autoantigens/genetics , Epidermis/growth & development , Mice , Non-Fibrillar Collagens/deficiency , Non-Fibrillar Collagens/genetics , Skin , Collagen Type XVIIABSTRACT
Apalutamide, an oral androgen receptor signaling inhibitor, is approved for the treatment of non-metastatic castration-resistant prostate cancer and metastatic prostate cancer. In the international randomized placebo-controlled clinical trials, apalutamide was associated with a higher rate of rash than placebo. However, given that reports from a dermatological perspective are limited, the skin manifestations and histopathology of the skin lesions caused by apalutamide are largely unknown. Here, we report a case of apalutamide-induced drug eruption. A 66-year-old man developed itchy maculopapular erythema on the trunk and extremities 10 weeks after starting apalutamide for progressive prostate cancer. A biopsy specimen showed interface dermatitis with perivascular lymphocytic infiltration in the upper dermis. The lymphocyte transformation test was positive for apalutamide. The skin manifestations improved after discontinuation of apalutamide and treatment with topical corticosteroids and systemic prednisolone. A review of the dermatology literature on apalutamide-induced drug eruption yielded only six cases, including our case. Dermatologically, there were four cases of maculopapular rash and two of toxic epidermal necrolysis and histopathologically, there were three cases of interface dermatitis, two of epidermal necrosis, and one of spongiotic dermatitis. Four patients had peripheral eosinophilia. A lymphocyte transformation test was performed in three cases and was positive for apalutamide in all cases. Except for the two cases of toxic epidermal necrolysis, which were fatal, the skin eruptions appeared 10 weeks after starting apalutamide. Considering the increasing number of patients with prostate cancer being treated with apalutamide, cases of apalutamide-induced drug eruption need to be accumulated and analyzed.
Subject(s)
Drug Eruptions , Exanthema , Prostatic Neoplasms , Stevens-Johnson Syndrome , Male , Humans , Aged , Androgen Receptor Antagonists/adverse effects , Drug Eruptions/etiology , Drug Eruptions/drug therapy , Exanthema/chemically induced , Prostatic Neoplasms/complicationsSubject(s)
Drug Hypersensitivity Syndrome , Eosinophilia , Pharmaceutical Preparations , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/therapy , Eosinophilia/chemically induced , Eosinophilia/diagnosis , Humans , Lenalidomide/adverse effectsABSTRACT
Type XVII collagen (COL17) is a transmembrane protein expressed in the basal epidermis. COL17 serves as a niche for epidermal stem cells, and although its reduction has been implicated in altering cell polarity and ageing of the epidermis, it is unknown how COL17 affects epidermal cell polarity. Here, we uncovered COL17 as a binding partner of the aPKC-PAR complex, which is a key regulating factor of cell polarity. Immunoprecipitation-immunoblot assay and protein-protein binding assay revealed that COL17 interacts with aPKC and PAR3. COL17 deficiency or epidermis-specific aPKCλ deletion destabilized PAR3 distribution in the epidermis, while aPKCζ knockout did not. Asymmetrical cell division was pronounced in COL17-null neonatal paw epidermis. These results show that COL17 is pivotal for maintaining epidermal cell polarity. Our study highlights the previously unrecognized role of COL17 in the basal keratinocytes.
Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Autoantigens/metabolism , Cell Cycle Proteins/metabolism , Cell Polarity , Epidermis/metabolism , Non-Fibrillar Collagens/metabolism , Protein Kinase C/metabolism , Animals , Autoantigens/genetics , HEK293 Cells , Humans , Mice , Mice, Knockout , Non-Fibrillar Collagens/genetics , Protein Isoforms/metabolism , Collagen Type XVIISubject(s)
Acrospiroma/diagnosis , Biomarkers, Tumor/metabolism , Carcinoma, Adenoid Cystic/diagnosis , Neoplasms, Complex and Mixed/diagnosis , Sweat Gland Neoplasms/diagnosis , Acrospiroma/pathology , Acrospiroma/surgery , Aged , Antigens, CD/analysis , Antigens, CD/metabolism , Biomarkers, Tumor/analysis , Biopsy , Carcinoma, Adenoid Cystic/pathology , Carcinoma, Adenoid Cystic/surgery , Hair Follicle/cytology , Hair Follicle/metabolism , Humans , Keratin-15/analysis , Keratin-15/metabolism , Leg , Male , Neoplasms, Complex and Mixed/pathology , Neoplasms, Complex and Mixed/surgery , Stem Cells/metabolism , Sweat Gland Neoplasms/pathology , Sweat Gland Neoplasms/surgery , Sweat Glands/pathology , Sweat Glands/surgerySubject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Dermatologic Agents/adverse effects , Eosinophilia/chemically induced , Interleukin-17/antagonists & inhibitors , Pleural Effusion/chemically induced , Psoriasis/drug therapy , Receptors, Interleukin-17/antagonists & inhibitors , Drug Substitution , Eosinophilia/diagnosis , Humans , Infliximab/therapeutic use , Interleukin-17/immunology , Male , Pleural Effusion/diagnosis , Psoriasis/diagnosis , Psoriasis/immunology , Receptors, Interleukin-17/immunology , Treatment OutcomeSubject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Dermatitis, Atopic/drug therapy , Diagnostic Errors , Immunosuppressive Agents/therapeutic use , Mycosis Fungoides/diagnosis , Skin Neoplasms/diagnosis , Dermatitis, Atopic/diagnosis , Humans , Male , Middle Aged , Mycosis Fungoides/therapy , Skin Neoplasms/therapy , Steroids/therapeutic use , Ultraviolet TherapySubject(s)
Hemangiosarcoma/therapy , Lymphangiosarcoma/therapy , Neoplasm Recurrence, Local/drug therapy , Protein Kinase Inhibitors/administration & dosage , Pyrimidines/administration & dosage , Skin Neoplasms/therapy , Sulfonamides/administration & dosage , Aged , Amputation, Surgical , Amputation Stumps/pathology , Biopsy , Chemoradiotherapy/methods , Disease Progression , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Hemangiosarcoma/pathology , Humans , Indazoles , Leg/surgery , Lymphangiosarcoma/pathology , Neoplasm Recurrence, Local/pathology , Progression-Free Survival , Skin/pathology , Skin Neoplasms/pathologyABSTRACT
Sox13, a group D member of the Sry-related high-mobility group box (Sox) transcription factor family, is expressed in various tissues including the hair follicle. However, its spatiotemporal expression patterns in the hair follicle and its role in hair development remain to be elucidated. To address these questions, we generated Sox13-LacZ-knock-in mice (Sox13LacZ/+), in which the LacZ reporter gene was inserted in-frame into exon 2, which contains the translation initiation codon. X-gal staining in Sox13LacZ/+ embryos revealed that Sox13 is initially expressed in the epithelial portion of the placode, and subsequently in the hair germ and the hair peg during early hair follicle development. In postnatal catagen and anagen, Sox13 was detected in the epithelial sheath, whereas in telogen, Sox13 was localized in the bulge region, where hair follicle stem cells reside. Immunohistochemistry with an anti-ß-galactosidase antibody and anti-hair keratin antibodies that specifically mark the different layers of the hair follicle revealed that Sox13 was predominantly expressed in the outer root sheath in anagen. However, the integumentary structures of Sox13LacZ/LacZ mice were grossly and histologically indistinguishable from those of wild type mice. These results suggest that although Sox13 is dispensable for epidermal and adnexal development, Sox13 is a useful marker for early hair follicle development.
Subject(s)
Autoantigens/genetics , Gene Expression Regulation, Developmental , Hair Follicle/growth & development , Spatio-Temporal Analysis , Animals , Autoantigens/analysis , Biomarkers , Connexins , Embryo, Mammalian , Hair Follicle/embryology , Immunohistochemistry , Mice , Mice, Transgenic , Transcription Factors/analysis , Transcription Factors/genetics , Zebrafish ProteinsABSTRACT
BACKGROUND: The epidermis possesses regenerative properties that become apparent only after wounding. Atypical protein kinase C (aPKC) isoforms aPKCζ and aPKCλ form a ternary complex with Par3 and Par6, and play crucial roles in establishing and maintaining epithelial cell polarity. The epidermal loss of aPKCλ results in progressive depletion of hair follicle stem cells. However, it is unclear whether aPKCs have equivalent activities in epidermal regeneration. OBJECTIVES: To clarify functional differences between aPKCζ and aPKCλ in cutaneous wound healing. METHODS: We compared cutaneous wound healing processes in vivo using mutant mice with genetic deletion of each aPKC isoform. We also analyzed functional differences between aPKCζ and aPKCλ in cell proliferation, directional cell migration, and formation of microtubules in vitro using primary keratinocytes established from each mutant mouse. RESULTS: Wound healing was significantly retarded in epidermis-specific aPKCλ knockout mice. In aPKCλ-deleted keratinocytes, the correct orientation of cell protrusions toward the wound was disrupted through the destabilization of Par6ß. The elongation of stabilized ß-tubulin was also deteriorated in aPKCλ-deleted keratinocytes, leading to defects in cell spreading. Conversely, wound healing and directional cell migration in aPKCζ-deleted mice were comparable to those in their control littermates. CONCLUSIONS: aPKCs are not functionally equivalent; aPKCλ, but not aPKCζ, plays a primary role in cutaneous wound healing.
Subject(s)
Cell Movement/physiology , Epidermis/injuries , Isoenzymes/physiology , Protein Kinase C/physiology , Wound Healing/physiology , Animals , Cell Polarity/physiology , Cells, Cultured , Epidermis/physiology , Keratinocytes/physiology , Mice , Mice, Knockout , Models, Animal , Primary Cell CultureABSTRACT
Incidence rates of cutaneous squamous cell carcinoma (SCC) are increasing in many countries. To estimate detailed trends of SCC incidence rates in the population of Akita Prefecture as the forerunner of super-aged societies, we conducted a retrospective analysis of patients diagnosed with SCC between 2007 and 2016 in Akita University Hospital. The crude SCC incidence rate increased rapidly between 2007 and 2016 from 2.5 to 10.0/100 000 people. Remarkably, the age-specific incidence rate of people aged 80 years or over increased between 2007 and 2016 from 14.7 to 51.6/100 000 people, suggesting that SCC incidence rates increase possibly due to not only the increased number of aged people but also because of unidentified cancer-prone environments. When the findings of the present study are generalized to other regions entering the era of super-aging, it is clear that we need to prepare for the economic disease burden together with careful monitoring to confirm future trends for SCC.